STRS Ohio’s Allogene Therapeutics ALLO Stock Holding History

STRS Ohio’s Portfolio ALLO Stock Details ALLO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-25,200	Closed	-$229K	–	2039
2022 Q1	$229K	Hold	25,200	–	–	﹤0.01%	1669
2021 Q4	$375K	Buy	25,200 +2,400	+11%	+$42.3K	﹤0.01%	1562
2021 Q3	$585K	Hold	22,800	–	–	﹤0.01%	1445
2021 Q2	$594K	Buy	+22,800	New	+$650K	﹤0.01%	1504
2021 Q1	–	Sell	-12,500	Closed	-$315K	–	2171
2020 Q4	$315K	Buy	12,500 +400	+3%	+$13K	﹤0.01%	1642
2020 Q3	$456K	Sell	12,100 -2,300	-16%	-$86.7K	﹤0.01%	1386
2020 Q2	$616K	Buy	+14,400	New	+$521K	﹤0.01%	1156
2019 Q2	–	Sell	-5,800	Closed	-$167K	–	2110
2019 Q1	$167K	Hold	5,800	–	–	﹤0.01%	1714
2018 Q4	$156K	Buy	+5,800	New	+$154K	﹤0.01%	1686

Other funds holding ALLO

TGA

TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

STRS Ohio's ALLO Position: Q2 2022 in Review

STRS Ohio sold out of Allogene Therapeutics (ALLO) in Q2 2022, closing a stake of 25,200 shares — an estimated $229K sold.

STRS Ohio first reported a position in ALLO in Q4 2018 and held it in 9 quarters. The position peaked at $616K in Q2 2020. 161 funds tracked by Wall St. Rank hold ALLO as of Q2 2022.

STRS Ohio reported no remaining Allogene Therapeutics position as of Q2 2022 after selling out during the quarter.
STRS Ohio sold 25,200 Allogene Therapeutics shares in Q2 2022, an estimated $229K.
STRS Ohio first reported a position in Allogene Therapeutics in Q4 2018 and held it in 9 quarters.
STRS Ohio's Allogene Therapeutics position peaked at $616K in Q2 2020.
161 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2022.

Based on STRS Ohio's 13F filing for Q2 2022, filed 25 Jul 2022.